MARKET

AKRO

Akero Therapeutics
AKRO
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-14.5563
-
4.574
4,499,030,919.25
NextCure To Merge With Avere Therapuetics In All-Stock Deal; NXTC Holders To Receive A Contingent Value Right For 90% Of Net Proceeds From Any Future License, Divestiture Or Monetization Of Its Pipeline Assets And Programs For Two Years; NXTC Also Announces $320M Private Placement
Benzinga · 07/14 10:05
Cantor Fitzgerald Suspends Overweight Rating on Akero Therapeutics
Benzinga · 12/10/2025 13:56
Akero Therapeutics Announces Merger and Delisting Plans
TipRanks · 12/09/2025 14:27
*Novo Nordisk Has Acquired Akero For $54 a Share Plus Additional $6 a Share Based on Milestones
Dow Jones · 12/09/2025 13:54
Weekly Report: what happened at AKRO last week (1201-1205)?
Weekly Report · 12/08/2025 09:05
Akero Therapeutics Shareholders Approve Novo Nordisk Merger
TipRanks · 12/03/2025 15:58
Akero Therapeutics Shareholders Approved Proposed Takeover By Novo Nordisk
Benzinga · 12/03/2025 15:46
NVO,LLY: Shares Drop as Word Health Organization Calls for Cheaper Versions of Weight-Loss Drugs
TipRanks · 12/01/2025 17:54
More

Webull offers Akero Therapeutics stock information, including NASDAQ: AKRO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKRO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AKRO stock methods without spending real money on the virtual paper trading platform.